Table 1 Patient characteristics at BL
Characteristic | Unit | All patients n = 147 |
|---|---|---|
Patient background | ||
Gender (male) | n (%) | 105 (71.4) |
Age | Years | 67.2 (61.4–71.8) |
Dialysis history | Years | 10.3 (5.6–17.1) |
DW | kg | 60.8 ± 13.5 |
Primary cause of ESRD | ||
CGN | n (%) | 69 (46.9) |
DM | n (%) | 51 (34.7) |
PKD | n (%) | 11 (7.5) |
NC | n (%) | 5 (3.4) |
RPGN | n (%) | 2 (1.4) |
Others · Unknown | n (%) | 9 (6.1) |
Dialysis condition | ||
3 times/week | n (%) | 147 (100) |
Time (4 h) | n (%) | 130 (88.4) |
Blood flow | mL/min | 220 (200–250) |
Modality (hemodialysis) | n (%) | 81 (55.1) |
(hemodiafiltration) | n (%) | 66 (44.9) |
Dialysate Ca (2.5 mEq/L) | n (%) | 98 (66.7) |
(3.0 mEq/L) | n (%) | 49 (33.3) |
Blood chemistries | ||
cCa | mg/dL | 8.75 ± 0.57 |
P | mg/dL | 5.10 ± 1.13 |
Mg | mg/dL | 2.44 + 0.39 |
i-PTH | pg/mL | 142 (92–230) |
ALP | U/L | 263 (212–344) |
Alb | g/dL | 3.7 (3.4–3.9) |
Prescription status | ||
Cinacalcet dose | mg/day | 25 (12.5–37.5) |
Phosphate binder user | n (%) | 128 (87.1) |
Ca carbonate user | n (%) | 97 (66.0) |
Dose | g/day | 2.5 (1.5–3.0) |
Oral VDRA user | n (%) | 31 (21.1) |
Alfacalcidol dose | μg/day | 0.5 (0.25–0.5) |
Calcitriol dose | μg/day | 0.25 (0.25–0.25) |
Intravenous VDRA user | n (%) | 96 (65.3) |
Dose | μg/month | 4.5 (2.5–6.5) |